Financial
FY2025 revenue $1.18bn (+6.5%); operating margin 0.4%; net income $2.1m.
Cash $196.5m; debt $167.6m.
Omnicell
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Fair
Customer rating
No reviews yet
Financial health
Band: FairListed: OMCL
FY2025 revenue $1.18bn (+6.5%); operating margin 0.4%; net income $2.1m.
Cash $196.5m; debt $167.6m.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$1.2bn | +6.5% | US$5.2m | US$2.1m | Omnicell |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Not yet researched.
Cyber & information governance
Not yet researched.
Regulatory & clinical safety
Not yet researched.
Contract performance
Not yet researched.
Competitors
No competitors linked yet.